Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer
This study aimed to examine the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) and other clinicopathological features in HER2+ MBC patients who received first-line anti-HER2 therapy. A total of 129 patients were assigned to NLR-low and NLR-high groups based on a cutoff value of 3.0 at...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/29/9/483 |
| _version_ | 1797489594335232000 |
|---|---|
| author | Bin Shao Xiaoran Liu Huiping Li Guohong Song Lijun Di Hanfang Jiang Ying Yan Ruyan Zhang Ran Ran Jiayang Zhang Yaxin Liu Huan Wang Jing Wang |
| author_facet | Bin Shao Xiaoran Liu Huiping Li Guohong Song Lijun Di Hanfang Jiang Ying Yan Ruyan Zhang Ran Ran Jiayang Zhang Yaxin Liu Huan Wang Jing Wang |
| author_sort | Bin Shao |
| collection | DOAJ |
| description | This study aimed to examine the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) and other clinicopathological features in HER2+ MBC patients who received first-line anti-HER2 therapy. A total of 129 patients were assigned to NLR-low and NLR-high groups based on a cutoff value of 3.0 at baseline. Peripheral blood lymphocyte subsets and gene mutations in circulating tumor DNA were analyzed by flow cytometry and Next-generation sequencing, respectively. Survival was evaluated by the Kaplan–Meier method and Cox regression analysis. Of the 129 patients, 77 and 52 were assigned to the NLR-low (≤3) and NLR-high (>3) groups, respectively. Compared with NLR-high patients, the NLR-low patients had significantly longer median progression-free survival (PFS) (11.7 vs. 7.7 months) (<i>p</i> = 0.001, HR = 2.703 95% CI 1.543–4.736 and overall survival (OS) (37.4 vs. 28.7 months) (<i>p</i> = 0.044, HR = 2.254 95% CI 1.024–4.924). Furthermore, this association was independent of metastatic sites or estrogen receptor status. Peripheral blood CD3+ (<i>p</i> = 0.034) and CD4+ (<i>p</i> = 0.010) T cell numbers were significantly higher in the NLR-low group than the NLR-high group. The mutational profile of MBC was generally similar between the two groups. Baseline NLR was a prognostic factor of PFS and OS for patients with HER2+ MBC in the first-line setting. These results may facilitate the selection of patients who will benefit most from anti-HER2 treatment. |
| first_indexed | 2024-03-10T00:19:46Z |
| format | Article |
| id | doaj.art-581def08b10246ecb54ca8772acdc8d8 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T00:19:46Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-581def08b10246ecb54ca8772acdc8d82023-11-23T15:45:33ZengMDPI AGCurrent Oncology1198-00521718-77292022-08-012996154616610.3390/curroncol29090483Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast CancerBin Shao0Xiaoran Liu1Huiping Li2Guohong Song3Lijun Di4Hanfang Jiang5Ying Yan6Ruyan Zhang7Ran Ran8Jiayang Zhang9Yaxin Liu10Huan Wang11Jing Wang12Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaThis study aimed to examine the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) and other clinicopathological features in HER2+ MBC patients who received first-line anti-HER2 therapy. A total of 129 patients were assigned to NLR-low and NLR-high groups based on a cutoff value of 3.0 at baseline. Peripheral blood lymphocyte subsets and gene mutations in circulating tumor DNA were analyzed by flow cytometry and Next-generation sequencing, respectively. Survival was evaluated by the Kaplan–Meier method and Cox regression analysis. Of the 129 patients, 77 and 52 were assigned to the NLR-low (≤3) and NLR-high (>3) groups, respectively. Compared with NLR-high patients, the NLR-low patients had significantly longer median progression-free survival (PFS) (11.7 vs. 7.7 months) (<i>p</i> = 0.001, HR = 2.703 95% CI 1.543–4.736 and overall survival (OS) (37.4 vs. 28.7 months) (<i>p</i> = 0.044, HR = 2.254 95% CI 1.024–4.924). Furthermore, this association was independent of metastatic sites or estrogen receptor status. Peripheral blood CD3+ (<i>p</i> = 0.034) and CD4+ (<i>p</i> = 0.010) T cell numbers were significantly higher in the NLR-low group than the NLR-high group. The mutational profile of MBC was generally similar between the two groups. Baseline NLR was a prognostic factor of PFS and OS for patients with HER2+ MBC in the first-line setting. These results may facilitate the selection of patients who will benefit most from anti-HER2 treatment.https://www.mdpi.com/1718-7729/29/9/483neutrophil-to-lymphocyte ratioHER2 positivemetastatic breast cancerprognosisanti-HER2 treatment |
| spellingShingle | Bin Shao Xiaoran Liu Huiping Li Guohong Song Lijun Di Hanfang Jiang Ying Yan Ruyan Zhang Ran Ran Jiayang Zhang Yaxin Liu Huan Wang Jing Wang Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer Current Oncology neutrophil-to-lymphocyte ratio HER2 positive metastatic breast cancer prognosis anti-HER2 treatment |
| title | Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer |
| title_full | Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer |
| title_fullStr | Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer |
| title_full_unstemmed | Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer |
| title_short | Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer |
| title_sort | prognostic value of pretreatment neutrophil to lymphocyte ratio in her2 positive metastatic breast cancer |
| topic | neutrophil-to-lymphocyte ratio HER2 positive metastatic breast cancer prognosis anti-HER2 treatment |
| url | https://www.mdpi.com/1718-7729/29/9/483 |
| work_keys_str_mv | AT binshao prognosticvalueofpretreatmentneutrophiltolymphocyteratioinher2positivemetastaticbreastcancer AT xiaoranliu prognosticvalueofpretreatmentneutrophiltolymphocyteratioinher2positivemetastaticbreastcancer AT huipingli prognosticvalueofpretreatmentneutrophiltolymphocyteratioinher2positivemetastaticbreastcancer AT guohongsong prognosticvalueofpretreatmentneutrophiltolymphocyteratioinher2positivemetastaticbreastcancer AT lijundi prognosticvalueofpretreatmentneutrophiltolymphocyteratioinher2positivemetastaticbreastcancer AT hanfangjiang prognosticvalueofpretreatmentneutrophiltolymphocyteratioinher2positivemetastaticbreastcancer AT yingyan prognosticvalueofpretreatmentneutrophiltolymphocyteratioinher2positivemetastaticbreastcancer AT ruyanzhang prognosticvalueofpretreatmentneutrophiltolymphocyteratioinher2positivemetastaticbreastcancer AT ranran prognosticvalueofpretreatmentneutrophiltolymphocyteratioinher2positivemetastaticbreastcancer AT jiayangzhang prognosticvalueofpretreatmentneutrophiltolymphocyteratioinher2positivemetastaticbreastcancer AT yaxinliu prognosticvalueofpretreatmentneutrophiltolymphocyteratioinher2positivemetastaticbreastcancer AT huanwang prognosticvalueofpretreatmentneutrophiltolymphocyteratioinher2positivemetastaticbreastcancer AT jingwang prognosticvalueofpretreatmentneutrophiltolymphocyteratioinher2positivemetastaticbreastcancer |